{"nct_id":"NCT06101134","title":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-04","start_date":"2023-11-06","start_date_type":"ACTUAL","primary_completion_date":"2025-04-10","primary_completion_date_type":"ACTUAL","completion_date":"2027-08-31","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["BMY"]}